Issue 2, 2012

Diaryl ureaLDV peptidomimetics as α4β1 integrin antagonists: synthesis, adhesion inhibition and toxicity evaluation on CCRF-CEM cell line

Abstract

The α4β1 (VLA-4) integrin plays an important role in the leukocytes migration to sites of inflammation and has been validated as a therapeutic target for treating inflammatory diseases. Two families of regioisomeric peptidomimetics based on the Leu-Asp-Val (LDV) motif recognized by the α4β1 integrin were synthesized. Their activity was evaluated through cell adhesion and cell detachment assays using the CCRF-CEM cell line (Human T cells lymphoblast-like). Among the 20 antagonists tested, 17 appeared to be a good inhibitor of the adhesion of CCRF-CEM to fibronectin with an IC50 value of 24 μM, comparable to the reference LDV peptide derivative 2. The toxicity of the peptidomimetics was also controlled.

Graphical abstract: Diaryl urea LDV peptidomimetics as α4β1 integrin antagonists: synthesis, adhesion inhibition and toxicity evaluation on CCRF-CEM cell line

Supplementary files

Article information

Article type
Concise Article
Submitted
08 Sep 2011
Accepted
17 Sep 2011
First published
19 Sep 2011

Med. Chem. Commun., 2012,3, 199-212

Diaryl urea LDV peptidomimetics as α4β1 integrin antagonists: synthesis, adhesion inhibition and toxicity evaluation on CCRF-CEM cell line

E. Gérard, A. Meulle, O. Feron and J. Marchand-Brynaert, Med. Chem. Commun., 2012, 3, 199 DOI: 10.1039/C1MD00229E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements